2025 Europe Adenovirus Vector Vaccine Market Revenue Opportunities Report
Description
The 2025 Europe Adenovirus Vector Vaccine Market Revenue Opportunities Report features 1) market size data for the region or country, 2) annual market growth rates, 3) the market's impact on related industries Medical and Surgical Hospitals, Offices of Physicians, and Medical Device Manufacturing, 4) Total Addressable Market (TOM) for the four largest market players, 5) Serviceable Addressable Market (SAM), and 6) Serviceable Obtainable Market (SOM)(Wharry Sharpe Research)
The Revenue Opportunities Reports provide market size data for a three-year historical trend (2019-2022), a three-year forecast estimate trends (2023-2025), and a five-year outlook projection (2026-2031) for the region or country. The report also features written analysis on market definitions, and market segments.
Market and product shipments include the total value of all products produced and shipped by all producers (also described as value of receipts, value of production, or value of work done.)
The report features written analysis and market size statistics on opportunities created in the Adenovirus Vector Vaccine Market by the changing related industries Medical and Surgical Hospitals, Offices of Physicians, and Medical Device Manufacturing,
The four largest companies actively involved in the adenovirus vector vaccine market in Europe include AstraZeneca, Janssen (Johnson & Johnson), BioNTech, and Valneva. AstraZeneca, in collaboration with Oxford University, developed Vaxzevria, one of the two adenovirus-based COVID-19 vaccines authorized in Europe, using a chimpanzee adenovirus vector. Janssen, part of Johnson & Johnson, produces a single-dose adenovirus vector vaccine using human adenovirus 26. BioNTech, known primarily for its mRNA vaccines, is expanding into adenoviral vector technologies and oncology immunotherapies. Valneva, based in France, specializes in vaccine development with a strong focus on infectious diseases using inactivated virus platforms and is advancing adenovirus-based vaccine candidates, including collaborations with Pfizer on Lyme disease vaccines.
Additionally, European viral vector manufacturing specialists like Lonza and Merck KGaA play vital roles by providing development and manufacturing services for adenoviral vector vaccines. Lonza manages the entire viral vector manufacturing lifecycle including adenoviral vectors, supporting several pharma and biotech clients, while Merck offers viral vector clearance technologies and contract manufacturing services to accelerate vaccine production. Valneva's distinct approach also includes whole-pathogen inactivated vaccines, complementing adenovirus vector technologies within Europe’s market expansion. This network of companies is driving innovation, clinical trials, and manufacturing capacities, sustaining Europe's active participation in adenovirus vector vaccine development and production.
Revenue Opportunities are defined by the measurements of Total Addressable Market (TOM) for the four largest market players, Serviceable Addressable Market (SAM), and Serviceable Obtainable Market (SOM). The measurements include both written analysis and current calculations for each company in the market for each country or region.
This report does not provide the names of companies in the market or written analysis of each market's trends within each country to provide a cost-effective report that focuses solely on the statistics and data on each market.
Wharry Sharpe Research publishes thousands of market analysis and product research report annually to assist their clients with the essential data they need for the market research, budgeting and forecasting needs.
The Revenue Opportunities Reports provide market size data for a three-year historical trend (2019-2022), a three-year forecast estimate trends (2023-2025), and a five-year outlook projection (2026-2031) for the region or country. The report also features written analysis on market definitions, and market segments.
Market and product shipments include the total value of all products produced and shipped by all producers (also described as value of receipts, value of production, or value of work done.)
The report features written analysis and market size statistics on opportunities created in the Adenovirus Vector Vaccine Market by the changing related industries Medical and Surgical Hospitals, Offices of Physicians, and Medical Device Manufacturing,
The four largest companies actively involved in the adenovirus vector vaccine market in Europe include AstraZeneca, Janssen (Johnson & Johnson), BioNTech, and Valneva. AstraZeneca, in collaboration with Oxford University, developed Vaxzevria, one of the two adenovirus-based COVID-19 vaccines authorized in Europe, using a chimpanzee adenovirus vector. Janssen, part of Johnson & Johnson, produces a single-dose adenovirus vector vaccine using human adenovirus 26. BioNTech, known primarily for its mRNA vaccines, is expanding into adenoviral vector technologies and oncology immunotherapies. Valneva, based in France, specializes in vaccine development with a strong focus on infectious diseases using inactivated virus platforms and is advancing adenovirus-based vaccine candidates, including collaborations with Pfizer on Lyme disease vaccines.
Additionally, European viral vector manufacturing specialists like Lonza and Merck KGaA play vital roles by providing development and manufacturing services for adenoviral vector vaccines. Lonza manages the entire viral vector manufacturing lifecycle including adenoviral vectors, supporting several pharma and biotech clients, while Merck offers viral vector clearance technologies and contract manufacturing services to accelerate vaccine production. Valneva's distinct approach also includes whole-pathogen inactivated vaccines, complementing adenovirus vector technologies within Europe’s market expansion. This network of companies is driving innovation, clinical trials, and manufacturing capacities, sustaining Europe's active participation in adenovirus vector vaccine development and production.
Revenue Opportunities are defined by the measurements of Total Addressable Market (TOM) for the four largest market players, Serviceable Addressable Market (SAM), and Serviceable Obtainable Market (SOM). The measurements include both written analysis and current calculations for each company in the market for each country or region.
This report does not provide the names of companies in the market or written analysis of each market's trends within each country to provide a cost-effective report that focuses solely on the statistics and data on each market.
Wharry Sharpe Research publishes thousands of market analysis and product research report annually to assist their clients with the essential data they need for the market research, budgeting and forecasting needs.
Table of Contents
51 Pages
- A. Definitions
- A1. Market Definition
- A2. Market Segmentation
- A3. Industry Opportunities-Industry1
- A4. Industry Opportunities-Industry2
- A5. Industry Opportunities-Industry3
- B. Total Addressable Market (TAM)
- B1. TAM-Player 1/4
- B2. TAM-Player 2/4
- B3. TAM-Player 3/4
- B4. TAM-Player 4/4
- C. Serviceable Addressable Market (SAM)
- C1. SAM-Player 1/4
- C2. SAM-Player 2/4
- C3. SAM-Player 3/4
- C4. SAM-Player 4/4
- D. Serviceable Obtainable Market (SOM)
- D1. SOM-Player 1/4
- D2. SOM-Player 2/4
- D3. SOM-Player 3/4
- D4. SOM-Player 4/4
- E. Appendix
Search Inside Report
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
